Hasan Basri Ergün

Dr. Hasan Basri Ergün

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
EDEsra Demir
Esra Demir
YOYunus Can Ozalp
Yunus Can Ozalp
HEHasan Basri Ergün
Hasan Basri Ergün
BUBurcu Uludag
Burcu Uludag
OOOktay Olmuşçelik
Oktay Olmuşçelik
OAOmar Alomari
Omar Alomari
Objective: We aimed to investigate the effects of a low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet on symptom severity, quality of life, and fecal zonulin levels in patients with irritable bowel syndrome (IBS). Methods: Twenty-four patients with IBS were prospectively randomized to either a low-FODMAP diet (LFD) or a traditional diet (TD) for 4 weeks. IBS Symptom Severity Scale (IBS-SSS), IBS Quality of Life (IBS-QOL), and fecal zonulin levels were assessed at baseline and week 4 in both groups. In the LFD group, FODMAP-containing foods were gradually reintroduced after week 4, and all assessments were repeated at week 16. Changes in laboratory parameters, fecal zonulin levels, IBS-SSS, and IBS-QOL scores were evaluated. Results: Fecal zonulin levels did not differ significantly between groups at baseline or week 4, and no significant within-group changes were observed over time (all p > 0.05). IBS-SSS scores improved significantly at week 4 in both groups compared with the baseline (p < 0.05), with no significant difference in the magnitude of improvement between groups (p > 0.05). In the LFD group, IBS-SSS scores increased at week 16 compared with week 4 (p < 0.05). Similarly, IBS-QOL scores improved significantly at week 4 in both groups (p < 0.05), without significant between-group differences (p > 0.05). In the LFD group, IBS-QOL scores returned to baseline levels by week 16. Conclusions: Both the LFD and TD were associated with significant short-term improvements in IBS symptom severity and quality of life. However, the LFD did not demonstrate superiority over the TD. Furthermore, no statistically significant changes in fecal zonulin levels were observed in either group, although these findings should be interpreted cautiously. In the LFD group, some improvements observed at week 4 were attenuated following FODMAP reintroduction at week 16; however, these findings represent exploratory within-group observations and should not be interpreted as evidence of long-term treatment efficacy or sustained benefit following FODMAP reintroduction.

7 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YMYasa Gul Mutlu
Yasa Gul Mutlu
EUEbrar Uzunabdullah
Ebrar Uzunabdullah
DYDuha İbrahim Yahya
Duha İbrahim Yahya
HEHasan Basri Ergün
Hasan Basri Ergün
SKSüreyya Yiğit Kaya
Süreyya Yiğit Kaya
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
Background/Objectives: Multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs) are at increased risk of venous thromboembolism (VTE). Standard prophylaxis typically involves aspirin or low-molecular-weight heparin (LMWH), guided by risk assessment tools such as SAVED and IMPEDE-VTE. However, these models have practical limitations, and real-world evidence supporting novel oral anticoagulants (NOACs) as primary prophylaxis remains limited. Methods: In this retrospective, single-center study, we analyzed 101 MM patients treated with IMiD-based therapy between January 2020 and December 2024. All patients received NOAC prophylaxis (apixaban 2.5 mg twice daily or rivaroxaban 10–20 mg once daily), irrespective of baseline thrombotic risk. Clinical characteristics, comorbidities, and treatment details were collected. The primary outcome was objectively confirmed VTE, while secondary outcomes included bleeding events and treatment feasibility, assessed by treatment continuation without clinically significant bleeding. Results: Median age was 63 years (range 35–89); 36.6% were female. Lenalidomide and pomalidomide were used in 86.1% and 13.9%, respectively. Twenty-eight patients (27.7%) had relapsed/refractory disease, while 72.3% were newly diagnosed. Over a median NOAC exposure of 6 months, two patients (2.0%) developed VTE (both deep vein thrombosis). One major bleeding event (1.0%) occurred. Conclusions: Universal NOAC prophylaxis in MM patients receiving IMiD-based therapy was associated with a low incidence of thromboembolic events and an acceptable safety profile. These real-world findings suggest that NOACs may represent a practical and effective alternative to aspirin or LMWH, potentially overcoming the limitations of score-based prophylaxis strategies.